Internal Medicine
Online ISSN : 1349-7235
Print ISSN : 0918-2918
ISSN-L : 0918-2918
47 巻, 6 号
選択された号の論文の18件中1~18を表示しています
ORIGINAL ARTICLES
  • Naro Ohashi, Akihiko Kato, Taro Misaki, Masanori Sakakima, Yoshihide F ...
    2008 年 47 巻 6 号 p. 485-491
    発行日: 2008年
    公開日: 2008/03/17
    ジャーナル オープンアクセス
    Objective Adiponectin (ADPN) has been shown to protect against cardiovascular disease for the general population with problematic metabolic syndrome. However, it remains unclear whether ADPN is associated with mortality in patients on maintenance hemodialysis (HD).
    Methods, Patients or Materials We selected 85 HD patients [51 men/34 women; mean age, 64±2 years; underlying kidney diseases, diabetic nephropathy in 36 patients (42.3%), chronic glomerulonephritis in 29 (34.1%), hypertensive nephrosclerosis in 10 (11.8%), and others in 10 (11.8%)] who survived for more than 3 months after the start of HD. We first measured serum ADPN levels and prospectively followed patients for the next 3 years.
    Results We were able to follow 74 of 85 patients; 59 survived, and 15 died. Serum log-transformed ADPN levels were negatively correlated with BMI (r=-0.43, p<0.01). Despite a similar BMI (20.7±0.8 vs. 20.3±0.4 kg/m2), the expired patients had significantly higher ADPN compared with the surviving patients (20.5 μg/ml [14.0-23.5] vs. 14.2 μg/ml [9.7-21.3], p<0.05). Cox-hazards multivariate regression analysis adjusted for conventional case-mix features (age, sex, and underlying kidney disease) revealed that serum ADPN became a significant determinant of all-cause mortality. There was a 10.3% risk increment for each 1-μg/ml increase in ADPN during the follow-up. Kaplan-Meier analysis revealed that patients with higher ADPN levels (≥15 μg/ml) had a significantly lower survival rate compared with those with lower ADPN levels (<15 μg/ml) (76 vs. 92%, p<0.05).
    Conclusion These results indicated that high rather than low ADPN independently predict total mortality in HD patients.
  • Tomoyuki Soma, Mitsunori Hino, Kozui Kida, Shoji Kudoh
    2008 年 47 巻 6 号 p. 493-501
    発行日: 2008年
    公開日: 2008/03/17
    ジャーナル オープンアクセス
    Objective We hypothesized that non-invasive positive pressure ventilation (NPPV) would improve an acute asthma attack in mild to moderate cases without bronchodilator therapy.
    Methodology A total of 44 eligible patients with acute asthma of mild to moderate severity who had acute attacks were randomly allocated to a NPPV (n=30) or control group (n=14). Both groups received intravenous infusion of hydrocortisone prior to the study. Patients in the NPPV group were divided into two subgroups at random: a high- (n=16) and a low-pressure group (n=14). The former had a fixed expiratory positive airway pressure and inspiratory positive airway pressure of 6 cmH2O and 8 cmH2O, respectively, while the latter had levels of 4 cmH2O and 6 cmH2O, respectively. Effects on the following variables were assessed: FEV1, oxygen saturation, heart rate, respiratory rate, scores of accessory muscle use and wheezing by auscultation, modified Borg scale score, and mean intra-airway pressure on the monitor.
    Results A total of 26 patients completed the study in the NPPV group. The mean percent change in FEV1 significantly improved after 40 minutes in the high-pressure group compared with that in the control group (p<0.0001). Similar significant improvements in modified Borg scale score and physical examination findings were observed in the high- and low-pressure groups. None of the patients required re-hospitalization or return to the emergency room in either the NPPV or control group.
    Conclusion We conclude that higher inflation pressure on NPPV led to clinical improvement in patients with acute asthma attacks of mild to moderate severity.
  • Shuwa Minami, Tomotaka Kawayama, Masao Ichiki, Mamoru Nishiyama, Yoshi ...
    2008 年 47 巻 6 号 p. 503-509
    発行日: 2008年
    公開日: 2008/03/17
    ジャーナル オープンアクセス
    Background There is insufficient evidence for the efficacy of a transdermal tulobuterol patch (TP), although combination therapy with bronchodilators is recommended for chronic obstructive pulmonary disease (COPD).
    Objective A randomized, controlled crossover study was conducted to evaluate the clinical efficacy and safety of the TP in 16 patients with COPD. Slow-release theophylline was used as a control drug.
    Methods Following a 2-week run-in period, patients were randomly allocated to two groups by the envelope method; they then received the TP and theophylline for 4 weeks each by the crossover method. Pulmonary function tests, peripheral blood examination, and electrocardiography were performed before and after each treatment period. Patients recorded in diaries their symptom scores, numbers of administrations of inhaled β2 agonists, and presence/absence of adverse reactions.
    Results Patients receiving TP exhibited significant improvement in the number and ease of sputum expectorations and in cough frequency score and wheezing severity score compared with baseline (p<0.05); the corresponding improvement in patients receiving theophylline was non-significant. Assessment of quality of life by the St. George's Hospital Respiratory Questionnaire revealed that treatment with TP was associated with significant improvement in symptoms, impact, and total scores compared with baseline (p<0.05); theophylline gave only a non-significant improvement in total score. Neither drug caused significant changes in the results of physiological examinations or in pulse or blood pressure. There was no difference in safety between the treatments.
    Conclusion Treatment of COPD patients with TP is more effective than with theophylline.
CASE REPORTS
PICTURES IN CLINICAL MEDICINES
feedback
Top